Market Outlook: Dealmaking and M&A for 2025
February 11, 2025
Despite an extended period of lower biopharma stock valuations and a start of declining interest rates, M&A totals remain historically low. With a new U.S. government administration taking office, and regulatory uncertainty, how will this affect M&A trends for 2025?
)
){kind=logo}
)
){kind=logo}
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}